SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
1.720
-0.030 (-1.71%)
Jul 3, 2025, 1:00 PM - Market closed

SAB Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
16356330340-
Upgrade
Market Cap Growth
-69.84%-44.79%113.36%-91.25%--
Upgrade
Enterprise Value
1096627336-
Upgrade
Last Close Price
1.723.796.885.9078.10-
Upgrade
PS Ratio
42.2226.4828.331.245.58-
Upgrade
PB Ratio
0.751.351.110.968.81-
Upgrade
P/TBV Ratio
0.751.351.110.968.81-
Upgrade
P/OCF Ratio
----170.89-
Upgrade
EV/Sales Ratio
26.246.9129.321.145.51-
Upgrade
Debt / Equity Ratio
0.320.180.100.190.220.21
Upgrade
Debt / EBITDA Ratio
-----0.38
Upgrade
Asset Turnover
0.010.020.030.360.881.48
Upgrade
Quick Ratio
1.332.615.231.371.563.00
Upgrade
Current Ratio
1.692.985.451.471.903.12
Upgrade
Return on Equity (ROE)
-92.35%-81.92%-95.51%-53.85%-44.21%86.15%
Upgrade
Return on Assets (ROA)
-48.28%-41.86%-35.30%-27.37%-12.16%34.47%
Upgrade
Return on Capital (ROIC)
-61.14%-57.16%-47.50%-43.00%-17.77%41.14%
Upgrade
Return on Capital Employed (ROCE)
-----45.20%
Upgrade
Earnings Yield
-214.47%-97.39%-66.52%-63.04%-5.05%-
Upgrade
FCF Yield
-197.40%-98.89%-39.91%-86.20%-2.64%-
Upgrade
Buyback Yield / Dilution
-41.12%-67.74%-26.86%-59.20%-1.21%23.30%
Upgrade
Updated Nov 6, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q